title: Management of bronchiolitis in infants and children.
authors.forename: M
authors.initials: M
authors.lastname: Viswanathan
authors.forename: V J
authors.initials: VJ
authors.lastname: King
authors.forename: C
authors.initials: C
authors.lastname: Bordley
authors.forename: A A
authors.initials: AA
authors.lastname: Honeycutt
authors.forename: J
authors.initials: J
authors.lastname: Wittenborn
authors.forename: A M
authors.initials: AM
authors.lastname: Jackman
authors.forename: S F
authors.initials: SF
authors.lastname: Sutton
authors.forename: K N
authors.initials: KN
authors.lastname: Lohr
mesh_terms: D000911:Antibodies, Monoclonal / Q000008:administration & dosage / Q000191:economics; D061067:Antibodies, Monoclonal, Humanized; D000998:Antiviral Agents / Q000008:administration & dosage / Q000191:economics; D001988:Bronchiolitis / Q000175:diagnosis* / Q000188:drug therapy / Q000517:prevention & control*; D002648:Child; D002675:Child, Preschool; D003362:Cost-Benefit Analysis; D019317:Evidence-Based Medicine; D017408:Guidelines as Topic; D006801:Humans; D007223:Infant; D007231:Infant, Newborn; D000069455:Palivizumab; D019141:Respiratory System Agents / Q000627:therapeutic use
chemical_list: D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000998:Antiviral Agents; D019141:Respiratory System Agents; D000069455:Palivizumab